FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559508740> ?p ?o ?g. }

• W2559508740 abstract "Abstract Abstract 4087 Introduction: Secondary primary malignancies (SPM) are an emerging issue in patients with multiple myeloma (MM) since the French IFM 99–02 trial has been closed as a consequence of a higher incidence of SPM in patients who had received lenalidomide as maintenance treatment compared to the patients in the placebo arm. Methods: To evaluate the incidence of SPM in the group of patients, who were treated with high-dose therapy (HDT) followed by autologous peripheral blood stem cell transplantation (PBSCT), we retrospectively looked at a homogeneous group of 313 consecutive patients, who were diagnosed with MM and had received HDT and autologous PBSCT at our hospital between December 1994 and January 2009. Induction treatment consisted of conventional chemotherapy without novel agents in 95% of patients and maintenance treatment was given with interferon or thalidomide in 37% und 35% of patients, respectively. Results: Within 313 patients with a median age of 55 (range: 31–74) years at diagnosis, we observed 18 (5.8%) patients who developed a SPM at various time points during the course of their disease. The number of patients who developed a solid neoplasm or a hematologic malignancy was identical. While the types of solid tumor observed varied greatly, we noted 8 patients with MDS/AML and only one patient with Hodgkins Disease. The median time from diagnosis of MM to the occurrence of SPM was 56 months (range: 14–127). The cumulative incidence of SPM was 19.7% with a rate of 0.7%, 5.8% and 15.7% at 2, 5 and 10 years after diagnosis without statistical differences between the group of patients with solid tumors (0.3%, 4.4%, 7.5%) and those with hematologic malignancies (0.4%, 1.8%, 9.3%). OS from the time of diagnosis in our group of 18 patients with SPM was not significantly different from that of patients without SPM with in median 70 and 83 months (p=0.7, HR 0.9 (0.5–1.7)), respectively. The same was true, when a landmark analysis was performed for patients alive after 2, 5 and 8 years with hazard ratios of 0.9 (95%CI 0.5–1.7, p=0.8), 0.6 (95%CI 0.3–1.4, p=0.2) and 1.0 (95%CI 0.2–4.3, p=1.0), respectively. In line with this finding, we found that survival time of more than 5 years from the time of diagnosis was the only prognostic parameter indicating a greater risk for the development of SPM (HR 4.7 (95%CI 1.1–19.8), p=0.04). In particular, we did not find any relationship to the incidence of SPM and the treatment with novel agents. The incidence rate of 206 patients, who were exposed to thalidomide was 6% (n=13, HR1.4 (95%CI 0.5–4.0), p=0.5), while of the 123 patients exposed to bortezomib 5 developed a SPM (4%, HR 0.4 (95%CI 0.1–1.1), p=0.1). There were two cases of SPM among the 71 patients following lenalidomide treatment (3%, HR 0.4 (95%CI 0.1–1.5), p=0.2). Having a closer look at the maintenance setting, which is associated with a longer duration of drug exposure, we did not find a higher incidence of SPM in patients treated with thalidomide maintenance after HDT in comparison to patients who had received interferon or no maintenance therapy (HR 1.0, 95%CI 0.3 – 3.2, p=1.0). Conclusions: In conclusion, the incidence of SPM in patients with MM treated with HDT is increased, especially for patients with a prolonged life span. SPM were not related to various treatment modalities including maintenance treatment with thalidomide. As a consequence on the available data, physicians should be aware of the risk of SPM and diagnostic measures to detect SPM should be included in the daily clinical workup of patients with MM. Disclosures: Fenk: Celgene: Consultancy, Research Funding; Ortho Biotec: Consultancy. Germing:Celgene: Consultancy, Research Funding. Gattermann:Celgene: Consultancy, Research Funding. Kobbe:Celgene: Consultancy, Research Funding; Ortho Biotec: Consultancy." @default.
• W2559508740 created "2016-12-08" @default.
• W2559508740 creator A5001433615 @default.
• W2559508740 creator A5005172825 @default.
• W2559508740 creator A5040572488 @default.
• W2559508740 creator A5042020284 @default.
• W2559508740 creator A5049125906 @default.
• W2559508740 creator A5053992861 @default.
• W2559508740 creator A5061663931 @default.
• W2559508740 creator A5068674008 @default.
• W2559508740 creator A5090048856 @default.
• W2559508740 date "2011-11-18" @default.
• W2559508740 modified "2023-10-01" @default.
• W2559508740 title "Secondary Primary Malignancies in Patients with Multiple Myeloma Treated with High-Dose Chemotherapy and Autologous Blood Stem Cell Transplantation," @default.
• W2559508740 doi "https://doi.org/10.1182/blood.v118.21.4087.4087" @default.
• W2559508740 hasPublicationYear "2011" @default.
• W2559508740 type Work @default.
• W2559508740 sameAs 2559508740 @default.
• W2559508740 citedByCount "1" @default.
• W2559508740 countsByYear W25595087402013 @default.
• W2559508740 crossrefType "journal-article" @default.
• W2559508740 hasAuthorship W2559508740A5001433615 @default.
• W2559508740 hasAuthorship W2559508740A5005172825 @default.
• W2559508740 hasAuthorship W2559508740A5040572488 @default.
• W2559508740 hasAuthorship W2559508740A5042020284 @default.
• W2559508740 hasAuthorship W2559508740A5049125906 @default.
• W2559508740 hasAuthorship W2559508740A5053992861 @default.
• W2559508740 hasAuthorship W2559508740A5061663931 @default.
• W2559508740 hasAuthorship W2559508740A5068674008 @default.
• W2559508740 hasAuthorship W2559508740A5090048856 @default.
• W2559508740 hasConcept C120665830 @default.
• W2559508740 hasConcept C121332964 @default.
• W2559508740 hasConcept C126322002 @default.
• W2559508740 hasConcept C141071460 @default.
• W2559508740 hasConcept C2776063141 @default.
• W2559508740 hasConcept C2776364478 @default.
• W2559508740 hasConcept C2776694085 @default.
• W2559508740 hasConcept C2777408962 @default.
• W2559508740 hasConcept C2778684742 @default.
• W2559508740 hasConcept C2779050716 @default.
• W2559508740 hasConcept C2779609412 @default.
• W2559508740 hasConcept C2911091166 @default.
• W2559508740 hasConcept C61511704 @default.
• W2559508740 hasConcept C71924100 @default.
• W2559508740 hasConcept C88879693 @default.
• W2559508740 hasConcept C90924648 @default.
• W2559508740 hasConceptScore W2559508740C120665830 @default.
• W2559508740 hasConceptScore W2559508740C121332964 @default.
• W2559508740 hasConceptScore W2559508740C126322002 @default.
• W2559508740 hasConceptScore W2559508740C141071460 @default.
• W2559508740 hasConceptScore W2559508740C2776063141 @default.
• W2559508740 hasConceptScore W2559508740C2776364478 @default.
• W2559508740 hasConceptScore W2559508740C2776694085 @default.
• W2559508740 hasConceptScore W2559508740C2777408962 @default.
• W2559508740 hasConceptScore W2559508740C2778684742 @default.
• W2559508740 hasConceptScore W2559508740C2779050716 @default.
• W2559508740 hasConceptScore W2559508740C2779609412 @default.
• W2559508740 hasConceptScore W2559508740C2911091166 @default.
• W2559508740 hasConceptScore W2559508740C61511704 @default.
• W2559508740 hasConceptScore W2559508740C71924100 @default.
• W2559508740 hasConceptScore W2559508740C88879693 @default.
• W2559508740 hasConceptScore W2559508740C90924648 @default.
• W2559508740 hasLocation W25595087401 @default.
• W2559508740 hasOpenAccess W2559508740 @default.
• W2559508740 hasPrimaryLocation W25595087401 @default.
• W2559508740 hasRelatedWork W1988265934 @default.
• W2559508740 hasRelatedWork W2015950109 @default.
• W2559508740 hasRelatedWork W2366002336 @default.
• W2559508740 hasRelatedWork W2518740313 @default.
• W2559508740 hasRelatedWork W2530875354 @default.
• W2559508740 hasRelatedWork W2533772490 @default.
• W2559508740 hasRelatedWork W2538114067 @default.
• W2559508740 hasRelatedWork W2549534011 @default.
• W2559508740 hasRelatedWork W2552976039 @default.
• W2559508740 hasRelatedWork W2558322760 @default.
• W2559508740 hasRelatedWork W2558854175 @default.
• W2559508740 hasRelatedWork W2567319327 @default.
• W2559508740 hasRelatedWork W2567594949 @default.
• W2559508740 hasRelatedWork W2589794500 @default.
• W2559508740 hasRelatedWork W2605415016 @default.
• W2559508740 hasRelatedWork W2608522660 @default.
• W2559508740 hasRelatedWork W2620526750 @default.
• W2559508740 hasRelatedWork W2980597188 @default.
• W2559508740 hasRelatedWork W2987787412 @default.
• W2559508740 hasRelatedWork W1945295697 @default.
• W2559508740 isParatext "false" @default.
• W2559508740 isRetracted "false" @default.
• W2559508740 magId "2559508740" @default.
• W2559508740 workType "article" @default.